Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes

• Published in: Circulation (New York, N.Y.) Vol. 135; no. 5; pp. 449 - 459
• Main Authors: Abadir, Peter M, Jain, Alka, Powell, Laura J, Xue, Qian-Li, Tian, Jing, Hamilton, Robert G, Bennett, David A, Finucane, Thomas, Walston, Jeremy D, Fedarko, Neal S
• Format: Journal Article
• Language: English
• Published: United States by the American College of Cardiology Foundation and the American Heart Association, Inc 31.01.2017
• Subjects: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists - therapeutic use; Autoantibodies - therapeutic use; Biomarkers - blood; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult; mortality; angiotensin receptor blockers; aging; inflammation; autoantibodies

BACKGROUND—Agonistic angiotensin II type I receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be utilized to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker (ARB) tr...